Literature DB >> 14503809

Oncogene HER-2 in canine mammary gland carcinomas: an immunohistochemical and chromogenic in situ hybridization study.

J Martin de las Mulas1, J Ordás, Y Millán, V Fernández-Soria, S Ramón y Cajal.   

Abstract

Immunohistochemical (IHC) HER-2/neu protein overexpression was found in 17.6% of canine mammary gland carcinomas, a percentage similar to that observed in human breast carcinoma, but there was no gene amplification by chromogenic in situ hybridization (CISH). Canine mammary carcinoma would be a suitable natural model of that subset of human breast carcinomas with HER-2 protein overexpression without gene amplification.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14503809     DOI： 10.1023/a:1024929730165

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN： 0167-6806            Impact factor:   4.872


  15 in total

1.  Investigation of HER2 expression in canine mammary tumors by antibody-based, transcriptomic and mass spectrometry analysis: is the dog a suitable animal model for human breast cancer?

Authors:  G P Burrai; A Tanca; M R De Miglio; M Abbondio; S Pisanu; M Polinas; S Pirino; S I Mohammed; S Uzzau; M F Addis; E Antuofermo
Journal:  Tumour Biol       Date:  2015-06-19

2.  Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification.

Authors:  A Gama; A Alves; F Schmitt
Journal:  Virchows Arch       Date:  2008-08-02       Impact factor: 4.064

3.  Columnar cell lesions of the canine mammary gland: pathological features and immunophenotypic analysis.

Authors:  Enio Ferreira; Helenice Gobbi; Bruna S Saraiva; Geovanni D Cassali
Journal:  BMC Cancer       Date:  2010-02-23       Impact factor: 4.430

Review 4.  Heat shock proteins in animal neoplasms and human tumours--a comparison.

Authors:  Mariarita Romanucci; Tania Bastow; Leonardo Della Salda
Journal:  Cell Stress Chaperones       Date:  2008-03-12       Impact factor: 3.667

5.  ErbB2 copy number gain is associated with adverse outcome in canine mammary carcinoma.

Authors:  Kosei Sakai; James Ken Chambers; Kazuyuki Uchida; Takayuki Nakagawa; Ryohei Nishimura; Tomohiro Yonezawa; Shingo Maeda
Journal:  J Vet Med Sci       Date:  2021-01-19       Impact factor: 1.267

6.  Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting.

Authors:  Josef Singer; Marlene Weichselbaumer; Thomas Stockner; Diana Mechtcheriakova; Yury Sobanov; Erika Bajna; Friedrich Wrba; Reinhard Horvat; Johann G Thalhammer; Michael Willmann; Erika Jensen-Jarolim
Journal:  Mol Immunol       Date:  2012-04       Impact factor: 4.407

7.  Heat shock protein expression in canine malignant mammary tumours.

Authors:  Mariarita Romanucci; Alessia Marinelli; Giuseppe Sarli; Leonardo Della Salda
Journal:  BMC Cancer       Date:  2006-06-27       Impact factor: 4.430

8.  Molecular-based tumour subtypes of canine mammary carcinomas assessed by immunohistochemistry.

Authors:  Francesco Sassi; Cinzia Benazzi; Gastone Castellani; Giuseppe Sarli
Journal:  BMC Vet Res       Date:  2010-01-28       Impact factor: 2.741

9.  Genome aberrations in canine mammary carcinomas and their detection in cell-free plasma DNA.

Authors:  Julia Beck; Silvia Hennecke; Kirsten Bornemann-Kolatzki; Howard B Urnovitz; Stephan Neumann; Philipp Ströbel; Franz-Josef Kaup; Bertram Brenig; Ekkehard Schütz
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

10.  Proto-oncogene HER-2 in normal, dysplastic and tumorous feline mammary glands: an immunohistochemical and chromogenic in situ hybridization study.

Authors:  Javier Ordás; Yolanda Millán; Rafaela Dios; Carlos Reymundo; Juana Martín de Las Mulas
Journal:  BMC Cancer       Date:  2007-09-20       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.